Inventiva S.A. logo
Inventiva S.A. IVA
$ 4.71 1.66%
report update icon

Quarterly report 2025-Q2
added 05-22-2026

Inventiva S.A. Income Statement 2024-2011 | IVA

Brief overview of financial performance at Inventiva S.A.

This overview is based on financial performance over the past five years. The revenue attributed to Inventiva S.A. moved from 7 million euros to 9.2 million euros between the two endpoints. The cumulative result was +31.4%, corresponding to roughly 5.6% per year. Sales increased steadily, although without strong acceleration.

The operating result measured by EBITDA moved from −30.3 million euros to −97.6 million euros, or −221.8%. EBITDA underperformed the top-line trend. EBITDA margin moved from −433.2% to −1060.6%. Operating return per unit of revenue declined.

Comparing the endpoints shows a move from −30.2 million euros to −184 million euros. The loss widened and increased the financial risk.

Overall conclusion

Signs of deterioration dominate the five-year picture. The positive side is supported by sales growth. The weaker side of the profile includes lower net income, a narrow EBITDA buffer and a declining EBITDA margin. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Inventiva S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

184 M 161 M 146 M 535 M 341 M - - - - - - - - -

Shares

59.8 M 45.4 M 41.4 M 39.2 M 23.5 M - - - - - - - - -

Historical Prices

3.07 3.55 3.53 13.7 14.5 - - - - - - - - -

Net Income

-184 M -110 M -54.3 M -49.6 M -33.6 M -30.2 M -33.6 M -17.2 M -7.05 M -8.82 M -7.49 M -7.13 M - -

Revenue

9.2 M 17.5 M 12.2 M 4.19 M 372 K 7 M 3.2 M 6.52 M 9.45 M 4.87 M 3.28 M 3.06 M - -

Operating Income

-97.6 M -103 M -57.1 M -52.1 M -29.7 M -30.3 M -32.9 M - - - - - - -

Interest Expense

12.2 M 5.18 M 584 K 138 K 66 K 3 K 4 K - - - - - - -

EBITDA

-97.6 M -103 M -57.1 M -52.1 M -29.7 M -30.3 M -33 M -20.2 M -11.8 M -14.6 M -13.2 M -12.3 M - -

Operating Expenses

- - - - - 36.2 M 36.4 M 27 M 21.5 M 19.7 M 16.8 M 15.5 M - -

General and Administrative Expenses

15.8 M 13.8 M 12.9 M 11.2 M 5.93 M 1.6 M 2.06 M 1.73 M 1.18 M 1.24 M 1.01 M 1.09 M - -

All numbers in EUR currency

Quarterly Income Statement Inventiva S.A.

2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

109 M 59.8 M 52 M 45.4 M 42 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-176 M -184 M -49 M -110 M -55.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

4.45 M 9.2 M 41 K 17.5 M 1.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-62.9 M -97.6 M -52.2 M -103 M -55 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

9.72 M 12.2 M 5.22 M 5.18 M 1.94 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-62.9 M -97.6 M -52.2 M -103 M -55 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

14.7 M 15.8 M 7.7 M 13.8 M 6.81 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

The income statement is one of the three key financial reports of a company Inventiva S.A. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.6 5.56 % $ 6.41 B israelIsrael
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 64.67 0.11 % $ 12.4 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.85 0.12 % $ 319 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.78 1.13 % $ 3.03 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 34.07 0.17 % $ 382 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 5.6 2.06 % $ 3.74 M usaUSA
Codexis Codexis
CDXS
$ 1.59 0.3 % $ 139 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.1 1.25 % $ 303 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 199.02 0.31 % $ 9.9 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.28 0.1 % $ 1.62 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aytu BioScience Aytu BioScience
AYTU
$ 2.25 0.45 % $ 14.1 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada